---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017843"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:50:32.547662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Fortress Biotech reports 17.5% net revenue gain to $59.3M in 9M 2022; gets Nasdaq bid-price deficiency

## Summary
- Net revenue for nine months ended Sep 30, 2022 was $59.3M, up 17.5% from the same period in 2021.
- Nasdaq notified Fortress that common stock bid price closed below $1.00 for 30 consecutive business days; compliance risk.
- Journey Medical, a partner, generated Q3 2022 total revenue of $16.1M, down from $19.6M in Q3 2021.
- Checkpoint Therapeutics approved a 1-for-10 reverse stock split; Avenue Therapeutics completed a 1-for-15 reverse split in Sep 2022.
- Board declared monthly dividends of $0.1953125 per share on Series A Preferred Stock for Oct, Nov, Dec 2022.

## SEC filing metadata
- accession: 0001558370-22-017843
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/0001558370-22-017843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/fbio-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017843
- JSON: https://secwatch.observer/filing/0001558370-22-017843.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017843.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported the first nine months of 2022 results: revenue $59.3 million.
  - Period: the first nine months of 2022
  - Revenue: $59.3 million
  - Result: reported results
  source text: Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/0001558370-22-017843-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.